Lack Of Funding Has "Hobbled" FDA Postmarketing Drug Safety Work – IoM
This article was originally published in The Pink Sheet Daily
Executive Summary
Substantially increased resources are needed to improve FDA's drug safety activities and implement IoM recommendations, report says.
You may also be interested in...
BIO Helps Launch Coalition To Increase FDA Funding, Reduce User Fees Reliance
The Coalition for a Stronger FDA will lobby the administration before shifting its focus to congressional appropriators.
BIO Helps Launch Coalition To Increase FDA Funding, Reduce User Fees Reliance
The Coalition for a Stronger FDA will lobby the administration before shifting its focus to congressional appropriators.
Sweeping Changes At CDER Recommended In IoM Drug Safety Report
Among solutions suggested is six-year fixed term for the FDA commissioner and appointment of external advisory board to oversee cultural changes.